Circulating microRNAs as novel prognosis biomarkers for head and neck squamous cell carcinoma

Hou, Bo; Ishinaga, Hajime; Midorikawa, Katsumi; Shah, Said Ahmad; Nakamura, Satoshi; Hiraku, Yusuke; Oikawa, Shinji; Murata, Mariko; Takeuchi, Kazuhiko

doi:10.1080/15384047.2015.1045692

Cited by 55 publications

(51 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Samples were tested for 16 HPV subtypes (HPV 6,11,16,18,31,33,35,39,45,51,52,56,58,59,66, and 68) using multiplexbased fluorescence PCR (F-HPV typing™, Genomed Diagnostics AG, Paisley, United Kingdom). Samples were tested for 16 HPV subtypes (HPV 6,11,16,18,31,33,35,39,45,51,52,56,58,59,66, and 68) using multiplexbased fluorescence PCR (F-HPV typing™, Genomed Diagnostics AG, Paisley, United Kingdom).…”

Section: Hpv16mentioning

confidence: 99%

“…20,35,47,69,75 Henson et al observed that downregulation of hsa-mir-100-5p is linked to heightened levels of proliferation and altered gene expression in OSCC cell lines. 20,35,47,69,75 Henson et al observed that downregulation of hsa-mir-100-5p is linked to heightened levels of proliferation and altered gene expression in OSCC cell lines.…”

Section: Hsa-mir-100-5pmentioning

confidence: 99%

“…DNA was isolated from fresh frozen tumor and control tissue samples using the InnuPrep Tissue DNA Kit on the InnuPure© C16 System (Jena Analytika, Jena, Deutschland) according to manufacturer's instructions. Samples were tested for 16 HPV subtypes (HPV 6,11,16,18,31,33,35,39,45,51,52,56,58,59,66, and 68) using multiplexbased fluorescence PCR (F-HPV typing™, Genomed Diagnostics AG, Paisley, United Kingdom). Fragments were separated and measured with the ABI, 3500 Genetic Analyzer (Life Technologies, Carlsbad, California).…”

Section: Hpv16mentioning

confidence: 99%

“…The role of hsa-mir-100-5p and hsa-mir-31-5p in the carcinogenesis has been described in a general manner in cell culture and mice studies. [32][33][34] Furthermore, they have been predescribed as potential tools for OSCC diagnostics via blood or oral swirl analysis, 20,[35][36][37] but to our knowledge, their prognostic role in OSCC remains unclear.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

MicroRNA expression patterns in oral squamous cell carcinoma: hsa‐mir‐99b‐3p and hsa‐mir‐100‐5p as novel prognostic markers for oral cancer

et al. 2019

View full text Add to dashboard Cite

Background MicroRNAs (miRNA) recently evolved as potential cancer biomarkers. Therefore, the aim of the present study was to evaluate the prognostic impact of eight miRNAs connected to oral squamous cell carcinoma (OSCC). Method Expression levels of hsa‐mir‐21‐5p, hsa‐mir‐29b‐3p, hsa‐mir‐31‐5p, hsa‐mir‐99a‐5p, hsa‐mir‐99b‐3p, hsa‐mir‐100‐5p, hsa‐mir‐143‐3p and hsa‐mir‐155‐5p were analyzed in tumor tissue (n = 36) and healthy oral mucosal tissue (n = 17) and correlated with clinical variables. Results of the study cohort were validated in an OSCC cohort of The Cancer Genome Atlas. Results Increased hsa‐mir‐99b‐3p expression level showed a tendency toward advanced tumor stages, and high levels of hsa‐mir‐100‐5p expression were associated with extracapsular extension. While a high expression level of hsa‐mir‐99b‐3p was associated with better survival, a high expression level of hsa‐mir‐100‐5p was correlated with a poorer survival in the study cohort. Conclusion Our results indicate that hsa‐mir‐99b‐3p and hsa‐mir‐100‐5p may serve as novel prognostic biomarkers in OSCC.

show abstract

Section: Hpv16mentioning

confidence: 99%

Section: Hsa-mir-100-5pmentioning

confidence: 99%

Section: Hpv16mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

MicroRNA expression patterns in oral squamous cell carcinoma: hsa‐mir‐99b‐3p and hsa‐mir‐100‐5p as novel prognostic markers for oral cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…First, several studies designed screening strategies to identify candidate miRNAs with diagnostic value by comparing the serum or plasma of cancer patients to that of healthy controls. Then, they analysed the levels of the candidate miRNAs in pre-and post-surgery samples from patients diagnosed with breast cancer, osteosarcoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, tongue squamous cell carcinoma and gastric cancer (67,83,(137)(138)(139)(140)(141).…”

Section: Before and After Tumour Removalmentioning

confidence: 99%

Cell‐free microRNAs in blood and other body fluids, as cancer biomarkers

Ortiz‐Quintero

2016

Cell Proliferation

View full text Add to dashboard Cite

The discovery of cell-free microRNAs (miRNAs) in serum, plasma and other body fluids has yielded an invaluable potential source of non-invasive biomarkers for cancer and other non-malignant diseases. miRNAs in the blood and other body fluids are highly stable in biological samples and are resistant to environmental conditions, such as freezing, thawing or enzymatic degradation, which makes them convenient as potential biomarkers. In addition, they are more easily sampled than tissue miRNAs. Altered levels of cell-free miRNAs have been found in every type of cancer analysed, and increasing evidence indicates that they may participate in carcinogenesis by acting as cell-to-cell signalling molecules. This review summarizes the biological characteristics and mechanisms of release of cell-free miRNAs that make them promising candidates as non-invasive biomarkers of cancer.

show abstract

Biological role and clinical value of miR‐99a‐5p in head and neck squamous cell carcinoma (HNSCC): A bioinformatics‐based study

et al. 2018

View full text Add to dashboard Cite

Micro RNA s (mi RNA s) are confirmed to be tumor promoters or suppressors in multiple squamous cell carcinomas ( SCC s). miR‐99a‐5p has been demonstrated to be downregulated in cancerous tissues, but its functional role in head and neck SCC ( HNSCC ) and its mechanism of action have not been fully elucidated. Here, we studied the expression of miR‐99a‐5p in HNSCC and performed a clinical value assessment and then extracted mature expression data from The Cancer Genome Atlas ( TCGA ) and microarrays from Gene Expression Omnibus ( GEO ). Furthermore, biological analysis was constructed via online prediction tools. The results revealed that miR‐99a‐5p expression was markedly lower in HNSCC tissues than in normal tissues, which also showed significance in the prognosis of HNSCC . However, its diagnostic value could not be verified due to the lack of body fluid samples. Additionally, miR‐99a‐5p was expressed at higher levels in patients with low histological grade neoplasms than those with high histological grade neoplasms. The age of the patient might also be a possible clinical parameter affecting miR‐99a‐5p expression. Furthermore, miR‐99a‐5p significantly influenced HNSCC progression by regulating the PI 3K‐Akt signaling pathway, in which the key target genes were upregulated in 519 HNSCC tissues compared to 44 normal tissues, as determined by the Gene Expression Profiling Interactive Analysis ( GEPIA ). In conclusion, our study may provide insights into the expression and mechanism of miR‐99a‐5p in HNSCC . Further studies are required to elucidate the role of miR‐99a‐5p and its potential clinical applications for HNSCC .

show abstract

Circulating microRNAs as novel prognosis biomarkers for head and neck squamous cell carcinoma

Cited by 55 publications

References 22 publications

MicroRNA expression patterns in oral squamous cell carcinoma: hsa‐mir‐99b‐3p and hsa‐mir‐100‐5p as novel prognostic markers for oral cancer

MicroRNA expression patterns in oral squamous cell carcinoma: hsa‐mir‐99b‐3p and hsa‐mir‐100‐5p as novel prognostic markers for oral cancer

Cell‐free microRNAs in blood and other body fluids, as cancer biomarkers

Biological role and clinical value of miR‐99a‐5p in head and neck squamous cell carcinoma (HNSCC): A bioinformatics‐based study

Contact Info

Product

Resources

About